suck pdf from google scholar
unlimited free pdf from europmc22572427    free
PDF from PMC    free
html from PMC    free
PDF vom PMID22572427  :  Publisher
PDF vom PMID22572427
suck pdf from library genesis
English Wikipedia

Nephropedia Template TP (

Twit Text


  • DeepDyve
  • Pubget Overpricing


  • lüll
  • Platelet adenosine diphosphate receptor antagonists: ticlopidine to ticagrelor-a long continuing journey
  • Kaul U; Mansoor AH
  • Indian Heart J 2012[Jan]; 64 (1): 54-9
  • Platelet aggregation plays a central role in the pathogenesis of atherothrombosis. Platelet adenosine diphosphate (ADP) receptor antagonists (ticlopidine, clopidogrel, prasugrel, and ticagrelor) are a major advance in the treatment of atherothrombotic diseases, especially acute coronary syndromes (ACS). Ticlopidine was the first thienopyridine introduced into clinical practice, but its potentially serious haematological side-effects limited its use and it was quickly eclipsed by clopidogrel. Clinical trials established aspirin plus clopidogrel as the standard dual anti-platelet therapy in patients with ACS and patients undergoing percutaneous coronary intervention (PCI) with stenting. Clopidogrel was found to have pharmacokinetic and pharmacodynamic limitations. Prasugrel is the next approved thienopyridine that has shown superior efficacy in ACS patients undergoing PCI in comparison to clopidogrel, although at the cost of a higher bleeding risk. Ticagrelor is the latest non-thienopyridine ADP receptor blocker that is potent, effective, reversible, and relatively safer as compared to clopidogrel. Both prasugrel and ticagrelor are more potent than clopidogrel. The data so far suggests that ticagrelor has a wider applicability in usage in patients with ACS as compared to prasugrel. Prasugrel however seems to be better tolerated. Search is on for newer more potent but safer anti-platelet agents.
  • |Adenosine/adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic use[MESH]
  • |Blood Platelets/*drug effects/metabolism[MESH]
  • |Hemorrhage/chemically induced[MESH]
  • |Humans[MESH]
  • |Percutaneous Coronary Intervention/*adverse effects[MESH]
  • |Platelet Aggregation Inhibitors/adverse effects/pharmacokinetics/*therapeutic use[MESH]
  • |Platelet Aggregation/drug effects[MESH]
  • |Practice Guidelines as Topic[MESH]
  • |Purinergic P2Y Receptor Antagonists/adverse effects/pharmacokinetics/*therapeutic use[MESH]
  • |Risk Factors[MESH]
  • |Thrombosis/blood/etiology/*prevention & control[MESH]
  • |Ticagrelor[MESH]
  • |Ticlopidine/adverse effects/pharmacokinetics/*therapeutic use[MESH]
  • |Treatment Outcome[MESH]





  • *{{pmid22572427}}
    *<b>[http://www.kidney.de/mlpefetch.php?search=22572427 Platelet adenosine diphosphate receptor antagonists: ticlopidine to ticagrelor-a long continuing journey ]</b> Indian Heart J 2012; 64(1) ; 54-9 Kaul U; Mansoor AH

        *22572427*

    Nephropedia PMID record

    Deutsche Wikipedia - im Artikel

    Hier den unten stehenden Textblock hineinkopieren

    Indian Heart J

    54 1.64 2012